Trichloroacetic Acid

Trichloroacetic Acid

SCHEMBL7710317

CN1CCCC1.O=C(O)C(Cl)(Cl)Cl

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
TSHR P16473 2/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HTT P42858 1/20 0.35
LMNA P02545 2/20 0.34
KMT2A Q03164 3/20 0.34
CHRM1 P11229 1/20 0.33
KDM4E B2RXH2 2/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
CA12 O43570 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Methylpiperidine SCHEMBL7712917 0.98 ALDH1A1 (0.48) ALDH1A1TSHRTP53CYP1A2TDP1
Trifluoroacetic Acid SCHEMBL2265470 0.80 HRH4 (0.38) ALDH1A1CYP1A2TDP1HTTLMNA
Trifluoroacetic Acid SCHEMBL2265475 0.80 HRH4 (0.38) ALDH1A1CYP1A2TDP1HTTLMNA
Trifluoroacetic Acid SCHEMBL931484 0.80 HRH4 (0.38) ALDH1A1CYP1A2TDP1HTTLMNA
N-Methyl Pyrrolidine (Nmp) SCHEMBL9368873 0.78 KDM4E (0.44) ALDH1A1CYP1A2TDP1HTTLMNA
N-Methyl Pyrrolidine (Nmp) SCHEMBL1687141 0.78 CYP1A2 (0.50) ALDH1A1CYP1A2TDP1HTTLMNA
N-Methylpiperidine SCHEMBL2071509 0.78 ALDH1A1 (0.38) ALDH1A1CYP1A2TDP1HTTLMNA
N-Methylpiperidine SCHEMBL2072770 0.78 ALDH1A1 (0.38) ALDH1A1CYP1A2TDP1HTTLMNA
Trifluoroacetic Acid SCHEMBL2265017 0.78 ALDH1A1 (0.38) ALDH1A1CYP1A2TDP1HTTLMNA
N-Methylpiperidine SCHEMBL2071510 0.78 ALDH1A1 (0.38) ALDH1A1CYP1A2TDP1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US claimed
US-20250066860-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2025-02-27 US disclosed
US-12195803-B2 Methods and materials for assessing and treating cancer THE JOHNS HOPKINS UNIVERSITY (US) 2025-01-14 US disclosed
US-20200377956-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2020-12-03 US disclosed
EP-3665308-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER The Johns Hopkins University (US) 2020-06-17 EP disclosed
US-20190256924-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2019-08-22 US disclosed
WO-2019067092-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2019-04-04 WO disclosed
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US disclosed
EP-0958378-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY Rapigene, Inc. (US) 1999-11-24 EP disclosed
EP-0952228-A2 Compositions and methods for enhancing hybridization specificity Rapigene, Inc. (US) 1999-10-27 EP disclosed
WO-1998013527-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY RAPIGENE, INC. (US) 1998-04-02 WO disclosed